nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—vagina—rectum cancer	0.0489	0.0539	CbGeAlD
Thalidomide—NFKB1—seminal vesicle—rectum cancer	0.0478	0.0527	CbGeAlD
Thalidomide—CRBN—seminal vesicle—rectum cancer	0.04	0.0441	CbGeAlD
Thalidomide—NFKB1—renal system—rectum cancer	0.0385	0.0424	CbGeAlD
Thalidomide—NFKB1—urethra—rectum cancer	0.0378	0.0417	CbGeAlD
Thalidomide—NFKB1—mammalian vulva—rectum cancer	0.036	0.0397	CbGeAlD
Thalidomide—CRBN—renal system—rectum cancer	0.0323	0.0356	CbGeAlD
Thalidomide—CRBN—urethra—rectum cancer	0.0317	0.0349	CbGeAlD
Thalidomide—TNF—lymph node—rectum cancer	0.0316	0.0349	CbGeAlD
Thalidomide—FGFR2—epithelium—rectum cancer	0.0312	0.0344	CbGeAlD
Thalidomide—NFKB1—female reproductive system—rectum cancer	0.0308	0.034	CbGeAlD
Thalidomide—CRBN—mammalian vulva—rectum cancer	0.0302	0.0333	CbGeAlD
Thalidomide—FGFR2—smooth muscle tissue—rectum cancer	0.03	0.0331	CbGeAlD
Thalidomide—FGFR2—renal system—rectum cancer	0.0289	0.0319	CbGeAlD
Thalidomide—NFKB1—vagina—rectum cancer	0.0279	0.0307	CbGeAlD
Thalidomide—CRBN—female reproductive system—rectum cancer	0.0258	0.0285	CbGeAlD
Thalidomide—CRBN—vagina—rectum cancer	0.0234	0.0258	CbGeAlD
Thalidomide—FGFR2—female reproductive system—rectum cancer	0.0232	0.0255	CbGeAlD
Thalidomide—NFKB1—lymph node—rectum cancer	0.018	0.0199	CbGeAlD
Thalidomide—CRBN—lymph node—rectum cancer	0.0151	0.0167	CbGeAlD
Thalidomide—CYP2E1—seminal vesicle—rectum cancer	0.0118	0.0131	CbGeAlD
Thalidomide—PTGS1—seminal vesicle—rectum cancer	0.0114	0.0126	CbGeAlD
Thalidomide—CYP1A1—epithelium—rectum cancer	0.0113	0.0124	CbGeAlD
Thalidomide—PTGS2—seminal vesicle—rectum cancer	0.0109	0.012	CbGeAlD
Thalidomide—CYP1A2—renal system—rectum cancer	0.0106	0.0117	CbGeAlD
Thalidomide—CYP1A1—renal system—rectum cancer	0.0105	0.0115	CbGeAlD
Thalidomide—CYP1A1—urethra—rectum cancer	0.0103	0.0113	CbGeAlD
Thalidomide—CYP3A5—renal system—rectum cancer	0.0102	0.0113	CbGeAlD
Thalidomide—PTGS1—epithelium—rectum cancer	0.00991	0.0109	CbGeAlD
Thalidomide—CYP1A1—mammalian vulva—rectum cancer	0.00978	0.0108	CbGeAlD
Thalidomide—PTGS1—smooth muscle tissue—rectum cancer	0.00955	0.0105	CbGeAlD
Thalidomide—CYP2E1—renal system—rectum cancer	0.00954	0.0105	CbGeAlD
Thalidomide—PTGS2—epithelium—rectum cancer	0.00947	0.0104	CbGeAlD
Thalidomide—CYP2C19—vagina—rectum cancer	0.00941	0.0104	CbGeAlD
Thalidomide—CYP2E1—urethra—rectum cancer	0.00937	0.0103	CbGeAlD
Thalidomide—PTGS1—renal system—rectum cancer	0.00919	0.0101	CbGeAlD
Thalidomide—PTGS2—smooth muscle tissue—rectum cancer	0.00913	0.0101	CbGeAlD
Thalidomide—PTGS2—renal system—rectum cancer	0.00879	0.00968	CbGeAlD
Thalidomide—PTGS2—urethra—rectum cancer	0.00863	0.00951	CbGeAlD
Thalidomide—PTGS1—mammalian vulva—rectum cancer	0.0086	0.00947	CbGeAlD
Thalidomide—CYP1A1—female reproductive system—rectum cancer	0.00838	0.00924	CbGeAlD
Thalidomide—CYP2C9—female reproductive system—rectum cancer	0.00806	0.00889	CbGeAlD
Thalidomide—CYP2E1—female reproductive system—rectum cancer	0.00764	0.00842	CbGeAlD
Thalidomide—CYP1A1—vagina—rectum cancer	0.00758	0.00835	CbGeAlD
Thalidomide—CYP3A5—vagina—rectum cancer	0.00741	0.00817	CbGeAlD
Thalidomide—PTGS1—female reproductive system—rectum cancer	0.00736	0.00811	CbGeAlD
Thalidomide—PTGS2—female reproductive system—rectum cancer	0.00704	0.00776	CbGeAlD
Thalidomide—PTGS1—vagina—rectum cancer	0.00666	0.00734	CbGeAlD
Thalidomide—PTGS2—vagina—rectum cancer	0.00636	0.00701	CbGeAlD
Thalidomide—CYP1A1—lymph node—rectum cancer	0.0049	0.0054	CbGeAlD
Thalidomide—PTGS1—lymph node—rectum cancer	0.00431	0.00475	CbGeAlD
Thalidomide—PTGS2—lymph node—rectum cancer	0.00412	0.00454	CbGeAlD
Thalidomide—FGFR2—SHC-mediated cascade—NRAS—rectum cancer	0.00163	0.0176	CbGpPWpGaD
Thalidomide—FGFR2—SHC-mediated cascade—KRAS—rectum cancer	0.00141	0.0152	CbGpPWpGaD
Thalidomide—FGFR2—SHC-mediated cascade—HRAS—rectum cancer	0.0012	0.0129	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—NRAS—rectum cancer	0.00119	0.0128	CbGpPWpGaD
Thalidomide—FGFR2—FRS2-mediated cascade—NRAS—rectum cancer	0.00117	0.0126	CbGpPWpGaD
Thalidomide—NFKB1—EPO signaling pathway—HRAS—rectum cancer	0.00116	0.0126	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR mutants—NRAS—rectum cancer	0.00115	0.0124	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—KRAS—rectum cancer	0.00102	0.011	CbGpPWpGaD
Thalidomide—FGFR2—FRS2-mediated cascade—KRAS—rectum cancer	0.00101	0.0109	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR mutants—KRAS—rectum cancer	0.000989	0.0107	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—NRAS—rectum cancer	0.000907	0.00978	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—NRAS—rectum cancer	0.000881	0.0095	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TYMS—rectum cancer	0.000879	0.00948	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—HRAS—rectum cancer	0.000871	0.00939	CbGpPWpGaD
Thalidomide—FGFR2—FRS2-mediated cascade—HRAS—rectum cancer	0.000856	0.00923	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR mutants—HRAS—rectum cancer	0.000841	0.00907	CbGpPWpGaD
Thalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—rectum cancer	0.000808	0.00872	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—KRAS—rectum cancer	0.000781	0.00842	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—KRAS—rectum cancer	0.000777	0.00838	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—HRAS—rectum cancer	0.000766	0.00826	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—KRAS—rectum cancer	0.000758	0.00818	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—NRAS—rectum cancer	0.000711	0.00767	CbGpPWpGaD
Thalidomide—NFKB1—Fc-epsilon receptor I signaling in mast cells—HRAS—rectum cancer	0.000695	0.00749	CbGpPWpGaD
Thalidomide—FGFR2—IRS-mediated signalling—NRAS—rectum cancer	0.000691	0.00745	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—TP53—rectum cancer	0.000691	0.00745	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—NRAS—rectum cancer	0.000684	0.00737	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TP53—rectum cancer	0.000682	0.00736	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—NRAS—rectum cancer	0.000679	0.00733	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—TP53—rectum cancer	0.000674	0.00727	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events—NRAS—rectum cancer	0.000672	0.00725	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TYMS—rectum cancer	0.00067	0.00722	CbGpPWpGaD
Thalidomide—NFKB1—LPA receptor mediated events—HRAS—rectum cancer	0.000669	0.00721	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events triggered by IGF1R—NRAS—rectum cancer	0.000666	0.00718	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—HRAS—rectum cancer	0.000664	0.00715	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—HRAS—rectum cancer	0.00066	0.00712	CbGpPWpGaD
Thalidomide—FGFR2—Insulin receptor signalling cascade—NRAS—rectum cancer	0.000649	0.00699	CbGpPWpGaD
Thalidomide—FGFR2—IGF1R signaling cascade—NRAS—rectum cancer	0.000649	0.00699	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—HRAS—rectum cancer	0.000645	0.00695	CbGpPWpGaD
Thalidomide—NFKB1—BCR signaling pathway—HRAS—rectum cancer	0.000645	0.00695	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—ITGA2—rectum cancer	0.000634	0.00684	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—KRAS—rectum cancer	0.000612	0.0066	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—NRAS—rectum cancer	0.000601	0.00648	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—NRAS—rectum cancer	0.000597	0.00644	CbGpPWpGaD
Thalidomide—FGFR2—IRS-mediated signalling—KRAS—rectum cancer	0.000595	0.00641	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—HRAS—rectum cancer	0.000589	0.00635	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—KRAS—rectum cancer	0.000588	0.00635	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—KRAS—rectum cancer	0.000585	0.00631	CbGpPWpGaD
Thalidomide—TNF—TGF-beta Receptor Signaling—HRAS—rectum cancer	0.000584	0.00629	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events—KRAS—rectum cancer	0.000579	0.00624	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—TP53—rectum cancer	0.000573	0.00618	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events triggered by IGF1R—KRAS—rectum cancer	0.000573	0.00618	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TP53—rectum cancer	0.000563	0.00607	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—rectum cancer	0.000561	0.00605	CbGpPWpGaD
Thalidomide—FGFR2—IGF1R signaling cascade—KRAS—rectum cancer	0.000558	0.00602	CbGpPWpGaD
Thalidomide—FGFR2—Insulin receptor signalling cascade—KRAS—rectum cancer	0.000558	0.00602	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—TP53—rectum cancer	0.000544	0.00587	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by Insulin receptor—NRAS—rectum cancer	0.000539	0.00581	CbGpPWpGaD
Thalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—rectum cancer	0.000534	0.00576	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—TP53—rectum cancer	0.000528	0.00569	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—NRAS—rectum cancer	0.000521	0.00562	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—HRAS—rectum cancer	0.00052	0.00561	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—TP53—rectum cancer	0.00052	0.0056	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—KRAS—rectum cancer	0.000518	0.00558	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—KRAS—rectum cancer	0.000514	0.00554	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—HRAS—rectum cancer	0.000509	0.00549	CbGpPWpGaD
Thalidomide—FGFR2—IRS-mediated signalling—HRAS—rectum cancer	0.000506	0.00545	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—HRAS—rectum cancer	0.0005	0.00539	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—rectum cancer	0.000498	0.00537	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HRAS—rectum cancer	0.000497	0.00536	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events—HRAS—rectum cancer	0.000492	0.0053	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events triggered by IGF1R—HRAS—rectum cancer	0.000487	0.00525	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—ITGA2—rectum cancer	0.000483	0.00521	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—rectum cancer	0.000483	0.00521	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Receptor Signaling Pathway—HRAS—rectum cancer	0.000479	0.00517	CbGpPWpGaD
Thalidomide—FGFR2—IGF1R signaling cascade—HRAS—rectum cancer	0.000475	0.00512	CbGpPWpGaD
Thalidomide—FGFR2—Insulin receptor signalling cascade—HRAS—rectum cancer	0.000475	0.00512	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by Insulin receptor—KRAS—rectum cancer	0.000464	0.005	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—NRAS—rectum cancer	0.000461	0.00497	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—TP53—rectum cancer	0.000457	0.00492	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—TP53—rectum cancer	0.00045	0.00485	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—KRAS—rectum cancer	0.000448	0.00483	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—NRAS—rectum cancer	0.000441	0.00476	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—NRAS—rectum cancer	0.000441	0.00476	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—HRAS—rectum cancer	0.00044	0.00474	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—HRAS—rectum cancer	0.000437	0.00471	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—NRAS—rectum cancer	0.000434	0.00468	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—rectum cancer	0.000429	0.00462	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—rectum cancer	0.000428	0.00462	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000424	0.00458	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—NRAS—rectum cancer	0.000422	0.00455	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—NRAS—rectum cancer	0.000415	0.00447	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—rectum cancer	0.000414	0.00447	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—NRAS—rectum cancer	0.000413	0.00445	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—NRAS—rectum cancer	0.000411	0.00443	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—rectum cancer	0.00041	0.00442	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—NRAS—rectum cancer	0.000409	0.0044	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—NRAS—rectum cancer	0.000405	0.00437	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.000403	0.00434	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—KRAS—rectum cancer	0.000397	0.00428	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—KRAS—rectum cancer	0.000396	0.00427	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by Insulin receptor—HRAS—rectum cancer	0.000394	0.00425	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—NRAS—rectum cancer	0.000384	0.00414	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—NRAS—rectum cancer	0.000384	0.00414	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—NRAS—rectum cancer	0.000384	0.00414	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—HRAS—rectum cancer	0.000381	0.00411	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—NRAS—rectum cancer	0.000381	0.00411	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—KRAS—rectum cancer	0.00038	0.00409	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—KRAS—rectum cancer	0.00038	0.00409	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—NRAS—rectum cancer	0.000378	0.00407	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—NRAS—rectum cancer	0.000376	0.00405	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—NRAS—rectum cancer	0.000375	0.00404	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—KRAS—rectum cancer	0.000374	0.00403	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.000365	0.00394	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—rectum cancer	0.000364	0.00393	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—KRAS—rectum cancer	0.000364	0.00392	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—KRAS—rectum cancer	0.000357	0.00385	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—NRAS—rectum cancer	0.000356	0.00384	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—KRAS—rectum cancer	0.000355	0.00383	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—KRAS—rectum cancer	0.000353	0.00381	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TP53—rectum cancer	0.000352	0.00379	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—KRAS—rectum cancer	0.000352	0.00379	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—HRAS—rectum cancer	0.00035	0.00377	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—KRAS—rectum cancer	0.000349	0.00376	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.000347	0.00374	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—NRAS—rectum cancer	0.000346	0.00374	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—NRAS—rectum cancer	0.00034	0.00367	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—HRAS—rectum cancer	0.000337	0.00364	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—KRAS—rectum cancer	0.000331	0.00357	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—KRAS—rectum cancer	0.000331	0.00357	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—KRAS—rectum cancer	0.000331	0.00357	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.000328	0.00354	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—KRAS—rectum cancer	0.000328	0.00353	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TP53—rectum cancer	0.000327	0.00352	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—KRAS—rectum cancer	0.000325	0.0035	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—KRAS—rectum cancer	0.000324	0.00349	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—rectum cancer	0.000323	0.00348	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—HRAS—rectum cancer	0.000323	0.00348	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—KRAS—rectum cancer	0.000323	0.00348	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—NRAS—rectum cancer	0.000322	0.00347	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—HRAS—rectum cancer	0.000318	0.00342	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—rectum cancer	0.000317	0.00342	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.00031	0.00335	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—KRAS—rectum cancer	0.000306	0.0033	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—HRAS—rectum cancer	0.000303	0.00327	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—HRAS—rectum cancer	0.000302	0.00325	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—HRAS—rectum cancer	0.0003	0.00324	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—HRAS—rectum cancer	0.000299	0.00322	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—KRAS—rectum cancer	0.000298	0.00322	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—rectum cancer	0.000298	0.00321	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000296	0.0032	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000295	0.00318	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.000293	0.00316	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000292	0.00314	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000281	0.00303	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—HRAS—rectum cancer	0.000281	0.00303	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HRAS—rectum cancer	0.000281	0.00303	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.000281	0.00303	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—HRAS—rectum cancer	0.000279	0.003	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—KRAS—rectum cancer	0.000277	0.00299	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.000276	0.00298	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—NRAS—rectum cancer	0.000276	0.00298	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—HRAS—rectum cancer	0.000275	0.00296	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—HRAS—rectum cancer	0.000274	0.00296	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—rectum cancer	0.000273	0.00295	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—rectum cancer	0.000263	0.00283	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—NRAS—rectum cancer	0.000262	0.00282	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—HRAS—rectum cancer	0.00026	0.00281	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—HRAS—rectum cancer	0.000253	0.00273	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.00025	0.00269	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000249	0.00269	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—rectum cancer	0.000246	0.00265	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000242	0.0026	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—KRAS—rectum cancer	0.000238	0.00256	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—rectum cancer	0.000232	0.0025	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—KRAS—rectum cancer	0.000225	0.00243	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—rectum cancer	0.000225	0.00243	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000222	0.0024	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.000205	0.00221	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—rectum cancer	0.000202	0.00218	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—HRAS—rectum cancer	0.000202	0.00218	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—rectum cancer	0.000192	0.00207	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—NRAS—rectum cancer	0.000178	0.00192	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—NRAS—rectum cancer	0.000157	0.0017	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.000155	0.00167	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—KRAS—rectum cancer	0.000153	0.00165	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NRAS—rectum cancer	0.000151	0.00163	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NRAS—rectum cancer	0.000149	0.00161	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NRAS—rectum cancer	0.000143	0.00155	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000137	0.00148	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NRAS—rectum cancer	0.000136	0.00146	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KRAS—rectum cancer	0.000135	0.00146	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—rectum cancer	0.00013	0.00141	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KRAS—rectum cancer	0.00013	0.0014	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KRAS—rectum cancer	0.000129	0.00139	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KRAS—rectum cancer	0.000123	0.00133	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KRAS—rectum cancer	0.000117	0.00126	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—rectum cancer	0.000115	0.00124	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—rectum cancer	0.000111	0.00119	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—rectum cancer	0.000109	0.00118	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—rectum cancer	0.000105	0.00113	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—rectum cancer	9.93e-05	0.00107	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TYMS—rectum cancer	9.7e-05	0.00105	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—rectum cancer	9.17e-05	0.000988	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—rectum cancer	8.7e-05	0.000938	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—rectum cancer	8.03e-05	0.000866	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—rectum cancer	7.89e-05	0.000851	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TYMS—rectum cancer	7.7e-05	0.000831	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—rectum cancer	7.49e-05	0.000807	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TYMS—rectum cancer	7.25e-05	0.000782	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TYMS—rectum cancer	7.24e-05	0.00078	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—rectum cancer	6.91e-05	0.000745	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TYMS—rectum cancer	6.84e-05	0.000737	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—rectum cancer	6.71e-05	0.000723	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—rectum cancer	6.36e-05	0.000686	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—rectum cancer	5.93e-05	0.000639	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—rectum cancer	5.87e-05	0.000633	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—rectum cancer	5.62e-05	0.000606	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TYMS—rectum cancer	5.59e-05	0.000603	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—rectum cancer	5.1e-05	0.00055	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TYMS—rectum cancer	5.1e-05	0.00055	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—rectum cancer	4.84e-05	0.000522	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—rectum cancer	4.53e-05	0.000489	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TYMS—rectum cancer	4.36e-05	0.00047	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—rectum cancer	4.34e-05	0.000468	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—rectum cancer	4.3e-05	0.000464	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—rectum cancer	4.11e-05	0.000444	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—rectum cancer	3.99e-05	0.00043	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—rectum cancer	3.43e-05	0.00037	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—rectum cancer	2.92e-05	0.000315	CbGpPWpGaD
